

Combo Rx for fibromyalgia tied to higher adherence

April 28 2017



(HealthDay)—Medication adherence is better for combination

prescription initiators with fibromyalgia syndrome (FMS), although expenditures for total health care are higher with combination prescriptions, according to a study published online April 18 in *Pain Practice*.

Nicole M. Marlow, Ph.D., from the University of Florida in Gainesville, and colleagues examined [medication adherence](#) and [health care](#) costs for combination prescription initiators (duloxetine/milnacipran/venlafaxine with pregabalin; 100 patients) versus monotherapy initiators (duloxetine, milnacipran, venlafaxine, and pregabalin; 1,771 patients combined) among patients with FMS. Claims data for the South Carolina Blue Cross Blue Shield State Health Plan were evaluated.

The researchers found that the odds ratios for high adherence were significantly increased (P health care were significantly higher (P

"Our findings suggest important clinical benefits with the use of combination prescription therapy, and prospective studies of medication adherence are warranted to examine causal relationships with outcomes not captured by health care claims databases," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Combo Rx for fibromyalgia tied to higher adherence (2017, April 28) retrieved 5 May 2024 from <https://medicalxpress.com/news/2017-04-combo-rx-fibromyalgia-tied-higher.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
